N-(5-(4-(5-amino-1,3,4-thiadiazol-2-yl)butyl)-1,3,4-thiadiazol-2-yl)-2-phenylacetamide | 1415397-18-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(5-(4-(5-amino-1,3,4-thiadiazol-2-yl)butyl)-1,3,4-thiadiazol-2-yl)-2-phenylacetamide
• 英文别名: N-[5-[4-(5-amino-1,3,4-thiadiazol-2-yl)butyl]-1,3,4-thiadiazol-2-yl]-2-phenylacetamide
• CAS: 1415397-18-0
• 化学式: C₁₆H₁₈N₆OS₂
• 分子量: 374.491
• InChiKey: CDZSRJONOQIGDJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  25
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  163
• 氢给体数：
  2
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  N-(5-(4-(5-amino-1,3,4-thiadiazol-2-yl)butyl)-1,3,4-thiadiazol-2-yl)-2-phenylacetamide 在 copper(l) iodide 、 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 1.0h， 生成 3-(1-benzyl-1H-1,2,3-triazol-4-yl)-N-(5-(4-(5-(2-phenylacetamido)-1,3,4-thiadiazol-2-yl)butyl)-1,3,4-thiadiazol-2-yl)propanamide
  参考文献：
  名称：

  含有三氮唑结构的谷氨酰胺酶GLS1抑制剂或其可药用的盐、其制备方法及用途

  摘要：

  本发明公开了含有三氮唑结构的谷氨酰胺酶GLS1抑制剂或其可药用的盐、其制备方法及用途，本发明的一系列含有三氮唑结构的化合物具有谷氨酰胺酶抑制活性，并可用于治疗与谷氨酰胺酶功能异常或谷氨酰胺酶活性升高相关的疾病和病症。这些化合物可有效结合在谷氨酰胺酶的变构位点，导致谷氨酰胺酶的构象发生变化，阻断其发挥生物学功能。体外实验表明：本发明化合物对于各类谷氨酰胺依赖的癌细胞，如结肠癌、三阴性乳腺癌、肺癌等均具有良好的抑制活性

  公开号：

  CN110746416A
• 作为产物：
  描述：

  甲基脂肪酰氯 在 三乙胺 、 三氯氧磷 作用下， 以 四氢呋喃 为溶剂， 反应 57.0h， 生成 N-(5-(4-(5-amino-1,3,4-thiadiazol-2-yl)butyl)-1,3,4-thiadiazol-2-yl)-2-phenylacetamide
  参考文献：
  名称：

  Design, Synthesis, and Pharmacological Evaluation of Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl Sulfide 3 (BPTES) Analogs as Glutaminase Inhibitors

  摘要：

  Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) is a potent and selective allosteric inhibitor of kidney-type glutaminase (GLS) that has served as a molecular probe to determine the therapeutic potential of GLS inhibition. In an attempt to identify more potent GLS inhibitors with improved drug-like molecular properties, a series of BPTES analogs were synthesized and evaluated. Our structure activity relationship (SAR) studies revealed that some truncated analogs retained the potency of BPTES, presenting an opportunity to improve its aqueous solubility. One of the analogs, N-(5-{2-[2-(5-amino-[1,3,4]thiadiazol-2-yl)-ethylsulfanyl]-ethyl}-[1,3,4]thiadiazol-2-yl)-2-phenylacetamide 6, exhibited similar potency and better solubility relative to BPTES and attenuated the growth of P493 human lymphoma B cells in vitro as well as in a mouse xenograft model.

  DOI：

  10.1021/jm301191p

文献信息

• [EN] HETEROCYCLIC INHIBITORS OF GLUTAMINASE<br/>[FR] INHIBITEURS HÉTÉROCYCLIQUES DE GLUTAMINASE
  申请人：CALITHERA BIOSCIENCES INC

  公开号：WO2013078123A1

  公开（公告）日：2013-05-30

  The invention relates to the heterocyclic compounds of Formula (I) as defined further herein, and pharmaceutical preparations thereof. The invention further relates to methods of treating cancer, immunological or neurological diseases using the heterocyclic compounds of the invention.

  本发明涉及式(I)定义的杂环化合物及其药物制剂。本发明进一步涉及使用本发明的杂环化合物治疗癌症、免疫性或神经疾病的方法。
• Novel 1,3,4-Selenadiazole-Containing Kidney-Type Glutaminase Inhibitors Showed Improved Cellular Uptake and Antitumor Activity
  作者：Zhao Chen、Di Li、Ning Xu、Jinzhang Fang、Yan Yu、Wei Hou、Haoqiang Ruan、Panpan Zhu、Renchao Ma、Shiying Lu、Danhui Cao、Rui Wu、Mowei Ni、Wei Zhang、Weike Su、Benfang Helen Ruan

  DOI：10.1021/acs.jmedchem.8b01198

  日期：2019.1.24

  improve the in vivo activity, we explored a bioisostere replacement of the sulfur atom in bis-2-(5-phenylacetamido-1,2,4-thiadiazol)ethyl sulfide and CB839 analogues with selenium using a novel synthesis of the selenadiazole moiety from carboxylic acids or nitriles. The resulting selenadiazole compounds showed enhanced KGA inhibition, more potent induction of reactive oxygen species, improved inhibition

  肾脏型谷氨酰胺酶[KGA /同工酶谷氨酰胺酶C（GAC）]正在成为癌症化疗中重要的肿瘤代谢靶标。它的变构抑制剂CB839在癌症治疗中显示了早期前景，但在体内癌症模型中的疗效有限。为了提高体内活性，我们使用硒的新合成硒代二唑部分，探索了用硒对双-2-（5-苯基乙酰胺基-1,2,4-噻二唑）乙基硫化物和CB839类似物中的硫原子进行生物等位置换。羧酸或腈。与相应的含硫分子相比，所得硒代二唑化合物显示出增强的KGA抑制作用，对活性氧的更有效诱导，对癌细胞的抑制作用改善以及更高的细胞和肿瘤积累。然而，CB839及其硒类似物均显示出对测试癌细胞的不完全抑制，并且在谷氨酰胺依赖性HCT116和侵袭性H22肝癌异种移植模型中均观察到肿瘤大小的部分减少。尽管如此，在用CB839的硒类似物治疗的动物中观察到肿瘤组织损伤和延长的生存期。
• HETEROCYCLIC INHIBITORS OF GLUTAMINASE
  申请人：Calithera Biosciences Inc.

  公开号：US20130157998A1

  公开（公告）日：2013-06-20

  The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel heterocyclic compounds of the invention.

  本发明涉及新型杂环化合物及其制药制剂。本发明还涉及使用所述新型杂环化合物治疗的方法。
• TREATMENT OF CANCER WITH HETEROCYCLIC INHIBITORS OF GLUTAMINASE
  申请人：Calithera Biosciences, Inc.

  公开号：US20150004134A1

  公开（公告）日：2015-01-01

  The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.

  本发明涉及新型杂环化合物及其制药制剂。本发明还涉及使用所述新型杂环化合物治疗或预防癌症的方法。
• Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy
  申请人：The Johns Hopkins University

  公开号：US10660861B2

  公开（公告）日：2020-05-26

  Currently available glutaminase inhibitors are generally poorly soluble, metabolically unstable, and/or require high doses, which together reduce their efficacy and therapeutic index. These can be formulated into nanoparticles and delivered safely and effectively for treatment of pancreatic cancer and other glutamine addicted cancers. Studies demonstrate that nanoparticle delivery of BPTES, relative to use of BPTES alone, can be safely administered and provides dramatically improved tumor drug exposure, resulting in greater efficacy. GLS inhibitors can be administered in higher concentrations with sub-100 nm nanoparticles, since the nanoparticles package the drug into “soluble” colloidal nanoparticles, and the nanoparticles deliver higher drug exposure selectively to the tumors due to the enhanced permeability and retention (EPR) effect. These factors result in sustained drug levels above the IC50 within the tumors for days, providing significantly enhanced efficacy compared to unencapsulated drug.

  目前可用的谷氨酰胺酶抑制剂通常溶解性差、代谢不稳定和/或需要高剂量，这些因素共同降低了其疗效和治疗指数。这些药物可配制成纳米颗粒，安全有效地用于治疗胰腺癌和其他谷氨酰胺上瘾的癌症。研究表明，与单独使用 BPTES 相比，纳米颗粒给药 BPTES 可以安全给药，并显著改善肿瘤药物暴露，从而提高疗效。使用 100 纳米以下的纳米颗粒可以施用更高浓度的 GLS 抑制剂，因为纳米颗粒将药物包装成 "可溶性 "胶体纳米颗粒，并且由于增强的渗透性和滞留（EPR）效应，纳米颗粒可以有选择性地向肿瘤提供更高的药物暴露量。这些因素使肿瘤内的药物浓度在数天内持续高于 IC50，与未封装的药物相比，疗效显著提高。